Statement: In the primary trial There was less than 3 days difference between the maximum recorded TTP of the Exemestane group and the Anastrozole group.
Primary_evidence: Outcome Measurement:    Time to Progression (TTP) - Expert Evaluation Committee Assessment   Time in months from randomization to first documentation of objective tumor progression or death due to breast cancer, whichever comes first. Tumor progression was determined by the expert evaluation committee using RECIST version 1.0 as an at least a 20% increase in the sum of the longest diameters (SLD) of the target lesions compared to the smallest SLD since the study treatment started. For participants with bone metastasis only, at least 25% increase in the measurable lesion according to General Rules for Clinical and Pathological Study of Breast Cancer (The 14th edition).   Time frame: Up to 2008 days of the treatment Results 1:    Arm/Group Title: Exemestane   Arm/Group Description: One tablet each of exemestane 25 mg and anastrozole placebo were orally administered once daily after a meal. The study treatment was continued until the disease progression or other discontinuation criteria were met.   Overall Number of Participants Analyzed: 147   Median (95% Confidence Interval)   Unit of Measure: months  13.8        (10.8 to 16.5) Results 2:    Arm/Group Title: Anastrozole   Arm/Group Description: One tablet each of anastrozole 1 mg and exemestane placebo were orally administered once daily after a meal. The study treatment was continued until the disease progression or other discontinuation criteria were met.   Overall Number of Participants Analyzed: 145   Median (95% Confidence Interval)   Unit of Measure: months  11.1        (10.8 to 16.6)